Kanyr is focused on three broadly applicable anti-cancer programs: PTP Inhibitor Immunotherapy - ImmunyrTM technology and PRL-PTP Inhibitors...
Our company is focused on the discovery of novel PTP inhibitors and harnessing their therapeutic potential...
We are actively seeking partnering opportunities, and collaborations with pharmaceutical and biotechnology companies to develop and commercialize our technologies